Skip to main content
S

SCL Science Inc. — Investor Relations & Filings

Ticker · 246960 ISIN · KR7246960009 KO Professional, scientific and technical activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2019-08-14 Audit Report / Informat…
Country KR South Korea
Listing KO 246960

About SCL Science Inc.

https://sclscience.com/en

SCL Science Inc., formerly InnoTherapy Inc., is a healthcare company focused on digital innovation and advanced medical technologies. The company develops and commercializes medical hemostatic agents based on its proprietary biomimetic technology, including the Bio-inspired Medical Materials (BiMM) product line. Leveraging 40 years of expertise in medical science, SCL Science is also dedicated to building a digital healthcare ecosystem using artificial intelligence and high-quality medical data. Its services extend to clinical trial analysis, bio-logistics, and an expanding drug discovery platform focused on AI-driven cancer vaccine development. The company serves hospitals, research laboratories, and other medical institutions.

Recent filings

Filing Released Lang Actions
[기재정정]사업보고서 (2018.12)
Audit Report / Information Classification · 1% confidence The document is a 'Correction Report' (정정신고) for a previously filed 'Business Report' (사업보고서), which is the Korean equivalent of a 10-K. It explicitly lists the 'Correction Subject' (정정대상 공시서류) as the '9th Business Report' and provides a table detailing the specific sections (Business Content, R&D, etc.) that were corrected. Since this is a formal regulatory filing amending a previously submitted annual report, it falls under the category of Regulatory Filings (RNS) as it is a miscellaneous regulatory update that does not fit into the primary report categories themselves. FY 2018
2019-08-14 Korean
타법인주식및출자증권취득결정
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from a Korean company (InnoTherapy) announcing the acquisition of shares in another company (NVC Partners). This type of disclosure, which details the acquisition of equity, the purpose of the investment, and the financial status of the target company, is classified as a corporate transaction or capital-related announcement. Given the specific categories provided, 'TAR' (M&A Activity) is the most appropriate classification for an announcement regarding the acquisition of shares in another entity.
2019-07-01 Korean
기타경영사항(특허권취득)(자율공시)(카테콜 기 및 산화된 카테콜 기가 도입되어 가교된 키토산으로 코팅된 무출혈 주사바늘)
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure from InnoTherapy regarding the acquisition of a patent for a 'hemostatic injection needle'. It is a voluntary disclosure (자율공시) of a specific corporate event (patent acquisition) rather than a financial report, earnings release, or management change. Since it does not fit into the specific categories like M&A, dividends, or share transactions, it falls under the general regulatory filing category.
2019-06-05 Korean
분기보고서 (2019.03)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for the company 'InnoTherapy' covering the period from January 1, 2019, to March 31, 2019. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2019
2019-05-14 Korean
기타경영사항(특허권취득)(자율공시)(카테콜 기 및 산화된 카테콜 기가 도입되어 가교된 키토산으로 코팅된 무출혈 주사바늘)
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure from InnoTherapy regarding the acquisition of a patent for a 'hemostatic injection needle'. It is filed as a 'voluntary disclosure' (자율공시) under the category of 'Other Management Matters' (기타 경영사항). Since it does not fit into specific categories like financial reports, board changes, or dividends, and is a standard regulatory announcement of a corporate event, it falls under the 'Regulatory Filings' (RNS) category.
2019-05-10 Korean
주요사항보고서(유형자산양수결정)
Capital/Financing Update Classification · 1% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korea Exchange (KRX) regarding the acquisition of tangible assets (real estate). This type of filing is a mandatory regulatory disclosure for material corporate events under the Capital Markets Act. Since it does not fit into specific categories like M&A (which usually refers to business combinations/takeovers), dividends, or financial reports, it falls under the general regulatory filing category.
2019-04-23 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.